CNSP — CNS Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $2.15m
- $1.90m
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 7.24 | 14 | 5 | 10.1 | 0.549 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7.89 | 15.5 | 7.48 | 12.6 | 1.59 |
Net Property, Plant And Equipment | 0.018 | 0.023 | 0.016 | 0.006 | 0.005 |
Other Long Term Assets | |||||
Total Assets | 7.91 | 15.9 | 8.76 | 13.1 | 1.7 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.311 | 1.91 | 2.59 | 4.92 | 6.13 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.311 | 1.91 | 2.59 | 4.92 | 6.13 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 7.6 | 13.9 | 6.16 | 8.13 | -4.43 |
Total Liabilities & Shareholders' Equity | 7.91 | 15.9 | 8.76 | 13.1 | 1.7 |
Total Common Shares Outstanding |